Volume 22, Number 3—March 2016
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
|Exposure||Stratifier||Multivariable regression, time ratio (95% CI)||p value|
|Xpert MTB/RIF||Previous TB|
|Conducted, rifampin-resistant TB||No||0.16 (0.12−0.21)||<0.001|
|Conducted, rifampin-resistant TB
|Previous TB||Xpert MTB/RIF|
|Yes||Not conducted||0.80 (0.62–1.04)||0.09|
|No||Conducted, rifampin-resistant TB||Baseline|
|Yes||Conducted, rifampin-resistant TB||1.69 (1.03–2.76)||0.04|
*Association between use of Xpert MTB/RIF and time to MDR TB treatment initiation was stratified by the effect modifier previous tuberculosis. Association between previous tuberculosis and time to MDR TB treatment initiation was stratified by Xpert use. There were 372 patients in the model. All results derived from the final model shown in Table 2. Median in baseline strata of Xpert MTB/RIF and previous tuberculosis was 41 days. MTB, Mycobacterium tuberculosis; RIF, rifampin. MDR TB, multidrug-resistant tuberculosis; NA, not applicable.
1These authors contributed equally to this article.